Objective:To observe effects of Nimotuzumab combined with concurrent chemoradiotherapy in treatment of patients with local advanced nasopharyngeal carcinoma.Methods:A prospective study was conducted on 60 patients with locally advanced nasopharyngeal carcinoma admitted to this hospital from January 2022 to January 2023.According to the random number table method,they were divided into control group and observation group,30 cases in each group.The control group was treated with concurrent chemoradiotherapy,while the observation group was treated with Nimotuzumab on the basis of that of the control group.The clinical efficacy,the tumor marker indexes[squamous cell carcinoma-associated antigen(SCCAg),cyto-keratin 19 fragment antigen 21-1(CYFRA21-1)]levels before and after the treatment,the incidence of adverse reactions,the disease recurrence rate,and the distant metastasis rate were compared between the two groups.Results:The objective response rate(ORR)of the observation group was 83.33%(25/30),which was higher than 60.00%(18/30)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of SCCAg and CYFRA21-1 in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there were no significant differences in the incidence of adverse reactions,the disease recurrence rate and the distant metastasis rate between the two groups(P>0.05).Conclusions:Nimotuzumab combined with concurrent chemoradiotherapy can improve ORR and reduce the levels of tumor markers in the patients with local advanced nasopharyngeal carcinoma.Moreover,it is superior to concurrent chemoradiotherapy.
关键词
局部晚期鼻咽癌/尼妥珠单抗/同期放化疗/肿瘤标志物/不良反应
Key words
Local advanced nasopharyngeal carcinoma/Nimotuzumab/Concurrent chemoradiotherapy/Tumor marker/Adverse reaction
维普
万方数据